AbbVie, Nimble
AbbVie Continues Deal-Making Spree With $200M Nimble Buy
The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and cement its long-term growth prospects following the Phase II failure of emraclidine in schizophrenia and in anticipation of market erosion for Skyrizi and Rinvoq,
But making AbbVie an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV ...
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...
As AbbVie Ireland’s new general manager, Dana Kendall will oversee the company’s commercial business in the country.
Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...
Shares of AbbVie Inc. ABBV inched 0.10% higher to $173.37 Friday, on what proved to be an all-around mixed trading session ...
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...
AbbVie ( ) has shared an update. AbbVie announced the retirement of Kevin K. Buckbee from his role as Senior Vice President, Controller, effective March 1, 2025, and the appointme ...
Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...
AbbVie has announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, ...
Pharmaceutical giant AbbVie Inc. has agreed to acquire Madison's Nimble Therapeutics Inc. for $200 million in cash.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback